TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical announced a board change with Harmesh Suniara stepping down as Non-Executive Director following a significant reduction in Lombard Odier Asset Management’s shareholding. The company, having secured a strong financial position through recent fundraising, is now concentrating on completing a strategic review and advancing its product development efforts, particularly Eroxon Intense and WSD4000, to strengthen its market position.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products. Their primary products include Eroxon®, a topical gel for erectile dysfunction, and development products WSD4000 and Eroxon® Intense. The company focuses on addressing unmet needs in the sexual health market for both men and women, with distribution partnerships in major markets such as the US and Europe.
Average Trading Volume: 2,956,141
Technical Sentiment Signal: Sell
Current Market Cap: £3.7M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.